Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2

Cancer

Volumn 117, Issue 24, 2011, Pages 5601-5611

  Kuczynski, Elizabeth A ^a,b   Viloria Petit, Alicia M ^a   Coomber, Brenda L ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

angiogenesis; colorectal carcinoma; endothelial cells; transforming growth factor beta; vascular endothelial growth factor receptor 2

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BONE MORPHOGENETIC PROTEIN 9; OXYGEN; SD 208; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; COW; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CACO-2 CELLS; CATTLE; CELL HYPOXIA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; GROWTH DIFFERENTIATION FACTORS; HCT116 CELLS; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80054964218     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26247     Document Type: Article

References (47)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
2. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of the NSABP Protocol C-08. J Clin Oncol. 2011; 29: 11-16.
3. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
4. Rapisarda A, Melillo G,. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009; 12: 74-80.
5. Shibuya M,. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. Biochem Mol Biol. 2006; 39: 469-478. (Pubitemid 44714526)
6. Fathers KE, Stone CM, Minhas K, et al. Heterogeneity of Tie2 expression in tumor microcirculation-influence of cancer type, implantation site, and response to therapy. Am J Pathol. 2005; 167: 1753-1762. (Pubitemid 41713325)
7. Patten SG, Adamcic U, Lacombe K, et al. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer. 2010; 10: 683.
8. Bergers G, Hanahan D,. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8: 592-603.
9. Massague J, Gomis RR,. The logic of TGFbeta signaling. FEBS Lett. 2006; 580: 2811-2820.
10. Levy L, Hill CS,. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006; 17: 41-58. (Pubitemid 43117515)
11. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996; 110: 375-382. (Pubitemid 26043869)
12. Grady W, Myeroff L, Swinler S, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 1999; 59: 320-324. (Pubitemid 29048861)
13. Pepper MS, Vassalli J, Orci L, Montesano R,. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res. 1993; 204: 356-363. (Pubitemid 23200200)
14. Seki T, Yun J, Oh S,. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res. 2003; 93: 682-689. (Pubitemid 37222165)
15. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003; 12: 817-828. (Pubitemid 37352776)
16. Donovan D, Harmey JH, Toomey D, et al. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol. 1997; 4: 621-627. (Pubitemid 127725489)
17. Mandriota SJ, Menoud P, Pepper MS,. Transforming growth factor beta1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J Biol Chem. 1996; 271: 11500-11505. (Pubitemid 26155993)
18. Minami T, Rosenberg RD, Aird WC,. Transforming growth factor-beta 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5′-untranslated region palindromic GATA site. J Biol Chem. 2001; 276: 5395-5402.
19. Minami T, Murakami T, Horiuchi K, et al. Interaction between Hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor signaling. J Biol Chem. 2004; 279: 20626-20635. (Pubitemid 38656457)
20. Bunz F, Dutriaux A, Lengauer C, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282: 1497-1501. (Pubitemid 28538613)
21. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T,. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993; 260: 85-88. (Pubitemid 23122749)
22. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol. 2002; 62: 58-64. (Pubitemid 34680516)
23. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med. 2005; 171: 889-898. (Pubitemid 40562720)
24. Northey JJ, Chmielecki J, Ngan E, et al. Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol. 2008; 28: 3162-3176. (Pubitemid 351657082)
25. Kowanetz M, Ferrara N,. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006; 12: 5018-5022. (Pubitemid 44453326)
26. Duff SE, Jeziorska M, Rosa DD, et al. Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy. Eur J Cancer. 2006; 42: 112-117. (Pubitemid 41814541)
27. Saltzman B, Yamamoto J, Decker R, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res. 2008; 68: 1236-1244. (Pubitemid 351272244)
28. Bakin A, Tomlinson A, Bhowmick N, et al. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000; 275: 36803-36810. (Pubitemid 32002090)
29. Djelloul S, Forgue-Lafitte M, Hermelin B, et al. Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells-status of the pRb1 and pRb2 tumor suppressor gene products. FEBS Lett. 1997; 406: 234-242. (Pubitemid 27166302)
30. Tesseur I, Zou K, Berber E, et al. Highly sensitive and specific bioassay for measuring bioactive TGF-beta. BMC Cell Biol. 2006; 7: 15.
31. Takiuchi H, Tada T, Li XF, et al. Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form. Cancer Res. 1992; 52: 5641-5646.
32. Agrez M, Chen A, Cone RI, et al. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol. 1994; 127: 547-556.
33. Jenkins G,. The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol. 2008; 40: 1068-1078.
34. Lehmann K, Janda E, Pierreux CE, et al. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 2000; 14: 2610-2622.
35. Dijke P, Goumans M, Pardali E,. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008; 11: 79-89.
36. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci. 2007; 120: 964-972. (Pubitemid 46638511)
37. Ren B, Yee K, Lawler J, Khosravi-Far R,. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 2006; 1765: 178-188.
38. Zhang Z, Neiva K, Lingen M, et al. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010; 17: 499-512.
39. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995; 44: 98-103.
40. Tuder RM, Flook BE, Voelkel NF,. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest. 1995; 95: 1798-1807.
41. Pazdrak B, Hein TW, Olszewska P, Carney DH,. Chronic hypoxia attenuates VEGF signaling and angiogenic responses by down-regulation of KDR in human endothelial cells. Am J Physiol. 2009; 296: 1162-1171.
42. Zhang H, Akman HO, Smith EL, et al. Cellular response to hypoxia involves signaling via Smad proteins. Blood. 2003; 101: 2253-2260. (Pubitemid 36302067)
43. Shao ES, Lin L, Yao Y, Bostrom KI,. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood. 2009; 114: 2197-2206.
44. David L, Mallet C, Keramidas M, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res. 2008; 102: 914-922. (Pubitemid 351591550)
45. Cunha S, Pardali E, Thorikay M, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med. 2010; 207: 81-100.
46. Suzuki Y, Ohga N, Morishita Y, et al. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci. 2010; 123: 1684-1692.
47. Dalal BI, Keown PA, Greenberg AH,. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol. 1993; 143: 381-389. (Pubitemid 24058193)